MRX (MRX) Stock Price & Analysis
MRX (MRX) rose 2.05% to USD 65.56 as of July 25, 2026 at 21:18 UTC, according to Nexqual real-time market data.
MRX last closed at USD 64.24; the session ranged USD 64.04–65.87 on volume of 467,763 shares. Market capitalization is —, with a 52-week range of USD 27.91–71.18 (NMS). Source: Nexqual, July 25, 2026 at 21:18 UTC.
Key Statistics (as of July 25, 2026 at 21:18 UTC)
| Price | USD 65.56 |
|---|---|
| Change | ▲ 2.05% (up) |
| Previous Close | USD 64.24 |
| Open | USD 65.43 |
| Day Range | USD 64.04 – 65.87 |
| 52-Week Range | USD 27.91 – 71.18 |
| Volume | 467,763 shares |
| Market Cap | — |
| Exchange | NMS |
Technical Analysis (MRX)
Nexqual's technical model rates MRX "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 21:18 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 56.46 (neutral) |
| vs SMA50 | Above (USD 60.66) |
| MACD | 0.99 (positive) |
Analyst Ratings (MRX)
Wall Street analysts rate MRX "Buy" based on 8 analysts, with a mean price target of USD 72.38 (range USD 36–82), per Nexqual as of July 25, 2026 at 21:18 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 72.38 |
| High Target | USD 82 |
| Low Target | USD 36 |
| Buy / Hold / Sell | 7 / 1 / 0 |
Earnings (MRX)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD 1.36 |
| Revenue Estimate | $625.28M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 1.48 vs est 1.38 ▲ beat |
| 2025-12-31 | USD 1.13 vs est 1.02 ▲ beat |
| 2025-09-30 | USD 0.96 vs est 0.94 ▲ beat |
| 2025-06-30 | USD 1.02 vs est 0.93 ▲ beat |
Source: Nexqual, July 25, 2026 at 21:18 UTC.
Financials & Fundamentals (MRX)
| Total Revenue | $3.27B |
|---|---|
| Revenue Growth (YoY) | +55.10% |
| Gross Margin | +68.86% |
| Operating Margin | +13.08% |
| Profit Margin | +10.63% |
| ROE | +29.06% |
| Debt / Equity | 974.13 |
| Current Ratio | 1.05 |
| Total Cash | $12.02B |
| Total Debt | $13.12B |
Source: Nexqual, July 25, 2026 at 21:18 UTC.
Financial Health Score (MRX)
Nexqual rates MRX's overall financial health "Solid" across five dimensions, as of July 25, 2026 at 21:18 UTC.
| Growth | Strong — Revenue +55% YoY (latest Q) |
|---|---|
| Profitability | Strong — Gross margin 69%, operating 13% |
| Balance Sheet | Critical — $12.0B cash vs $13.1B debt |
| Cash Flow | Mixed — No data |
| Efficiency | Strong — ROE 29%, ROA 1.1% |
Ownership (MRX)
| Insider Ownership | +15.34% |
|---|---|
| Institutional Ownership | +77.48% |
| Float | 50.88M |
| Short % of Float | +5.07% |
Source: Nexqual, July 25, 2026 at 21:18 UTC.
Leadership (MRX)
MRX is led by Paolo Roberto Tonucci (age 57), Chief Strategist & CEO of Capital Markets, per Nexqual as of July 25, 2026 at 21:18 UTC.
| Chief Strategist & CEO of Capital Markets | Paolo Roberto Tonucci (age 57) |
|---|---|
| President | Simon James Van Den Born (age 58) |
| Chief Technology Officer | Michael Dugan |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KG | Kestrel Group, Ltd. | USD 9.11 | ▼ 0.44% |
| TECH | Bio-Techne Corp | USD 71.6 | ▼ 0.25% |
| ALKS | Alkermes plc | USD 52.89 | ▲ 0.59% |
| NBIX | Neurocrine Biosciences, Inc. | USD 175.77 | ▲ 1.78% |
| CRL | Charles River Laboratories Inte | USD 226.58 | ▲ 3.6% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 21:18 UTC. This page is informational and not investment advice.